Login to Your Account



Cheaper tPA For Poor Countries

ThromboGenics: Another Deal For Staphylokinase Heart Drug

By Randall Osborne


Friday, October 5, 2007
ThromboGenics NV's licensing deal with Rhein Minapharma Biogenetics for preclinical THR-174 could bring a next-generation thrombolytic for developing countries, a cheaper therapy for heart attacks that's equivalent to the gold standard tissue plasminogen activator (tPA). (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription